Merck halts trial of once ‘promising’ Alzheimer’s drughealthmedicinetFebruary 16, 2017news Poor performance on a simple odor identification test was associated with a significantly increased risk of developing dementia years later, in a study of more than 2,400 older black and white adults led by Kristine Yaffe, … Related posts: HMN 2025: How NU-9 halts Alzheimer’s disease in animal model before symptoms begin HMN 2025: How An FDA-approved drug halts Epstein-Barr virus-driven lymphoma by disrupting a key cancer pathway HMN 2025: How Analysis of NRG trial in limited-stage small cell lung cancer suggests QOL benefit with twice- vs. once-daily radiation HMN 2025: How Once-weekly eloralintide leads to 20% weight loss in Phase II trial Previous Post Are Baked Lay’s potato chips "guilt-free"? PepsiCo says so Next Post Dermoscopy + triple light source reliable in ID of pityriasis rosea